- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02296216
Late Effects of Radiosurgery on Acromegaly Study (LateRAc)
LateR-Ac Study: Late Effects of Radiosurgery on Acromegaly Study
Transsphenoidal surgery is the first-line treatment of acromegaly. Adjunctive radiotherapy can be necessary when surgery is ineffective to avoid a prolonged medical treatment. Several studies reported long-term extra-pituitary side-effects of conventional radiotherapy. However, none has evaluated potential side-effects induced by Gamma Knife radiosurgery, a highly precise stereotactic technique, that has been used as an effective treatment of acromegaly.
Aims of the study: To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly.
Methods: Transversal exposed/unexposed study. Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion, whereas unexposed patients have been treated by somatostatin analogs after unsuccessful surgery for at least 10 years before inclusion. 80 Patients (40 patients/group) will be evaluated in terms of cognitive dysfunction, quality of life, secondary tumor, stroke, pituitary deficits and growth hormone control of hypersecretion. Recruitment is planned to last for 2 years.
Expected results: We should be able to determine whether Gamma Knife radiosurgery is a long-term safe technique. This result might modify the management and follow-up of patients with acromegaly unsuccessfully treated by surgery.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Marseille, France, 13354
- Assistance Publique Hopitaux de Marseille
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subject, man or woman, whose age is greater than or equal to 18 years;
- Subject has a combination of defined values plus Insulin Like Growth Factor-1 and no braking growth hormone (<1.2 milli-International unit/L) during an oral glucose tolerance acromegaly.
- Exposed: Subject with a surgically treated in remission with or without drug treatment somatostatinergic, acromegaly who received treatment with Gamma Knife radiosurgery within not less than 10 years and less than or equal to 20 years.
- Not exposed: Subject with a surgically treated acromegaly controlled by treatment somatostatinergic, not having received Gamma Knife radiosurgery.
- Subjects with thyroid under standardized assessment Levothyrox® inclusion in case of deficit associated thyroid stimulating;
- Topic supported in a project partner services;
- Subjects who have signed a written informed consent and agreeing to abide by the instructions of the protocol.
Exclusion Criteria:
- Minor or over the age of 75 years subject,
- Subjects with acromegaly resistant to somatostatinergic, or that required power is pegvisomant or cabergoline
- Subjects who received two pituitary neurosurgical treatment or treatment with conventional radiotherapy or radiosurgery treatments 2
- Pregnant or lactating woman,
- Topic is not affiliated with the social security system, or private about freedom;
- Subject refusing to participate in the study or not signing the informed consent;
- Subject with malignant disease known evolutionary
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Exposed patients
Exposed patients have been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
|
To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
|
|
Placebo Comparator: Unexposed patients
Unexposed patients have not been treated by Gamma Knife Radiosurgery after unsuccessful surgery 10-20 years before inclusion
|
To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The cognitive assessment measure a subject as cognitively preserved or cognitively impaired
Time Frame: 24 months
|
Assessment of cognitive functions based on:
|
24 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014-08
- RCAPHM14_0079 (Registry Identifier: APHM)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acromegaly
-
Andrea M. IsidoriCompletedAcromegaly CardiomyopathyItaly
-
Fondazione Policlinico Universitario Agostino Gemelli...RecruitingAcromegaly | Acromegaly Due to Pituitary AdenomaItaly
-
Camurus ABNot yet recruiting
-
Başakşehir Çam & Sakura City HospitalNot yet recruitingDifficult Intubation | Acromegaly Due to Pituitary Adenoma | Airway UltrasonographyTurkey (Türkiye)
-
University of CopenhagenOdense University Hospital; Aarhus University Hospital; Rigshospitalet, Denmark; Aalborg University Hospital and other collaboratorsCompletedAcromegaly Due to Pituitary AdenomaDenmark
-
IRCCS San RaffaeleFondazione Policlinico Universitario Agostino Gemelli IRCCS; University of... and other collaboratorsRecruiting
-
PfizerRecruiting
-
University Hospital, MontpellierRecruiting
-
Ginkgo Leaf Center for Rare DisordersRecruiting
Clinical Trials on Gamma Knife radiosurgery
-
Al-Azhar UniversityCompletedHypopituitarism | Pituitary Adenomas | Gamma Knife Radiosurgery | Long TermEgypt
-
Al-Azhar UniversityCompletedGamma Knife Radiosurgery | Tectal Plate GliomasEgypt
-
Elisabeth-TweeSteden ZiekenhuisZonMw: The Netherlands Organisation for Health Research and Development; Tilburg...CompletedNeoplasm MetastasesNetherlands
-
University of California, San FranciscoTerminated
-
Haukeland University HospitalCompleted
-
Swedish Medical CenterActive, not recruiting
-
Yale UniversityTerminatedMelanoma | Sarcoma | Renal Cell Carcinoma | Breast Cancer | Colorectal Cancer | Lung Cancer | Brain Metastases | Gastrointestinal CancersUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
CancerCare ManitobaHealth Sciences Centre Foundation, ManitobaTerminatedNeoplasm MetastasesCanada
-
The Cooper Health SystemWithdrawnMetastatic Cancer | Brain MetastasesUnited States